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The unexplained association between interferon respon-
siveness and serum low-density lipoprotein (LDL) in chronic
hepatitis C is likely due to oxidized LDL, a subfraction that
blocks viral cell entry by perturbing the interaction between
hepatitis C virus and its primary receptor.
BACKGROUND & AIMS: Hepatitis C virus (HCV) cell entry is
mediated by several cell surface receptors, including scavenger
receptor class B type I (SR-BI). Oxidized low density lipoprotein
(oxLDL) inhibits the interaction between HCV and SR-BI in a
noncompetitive manner. We tested whether serum oxLDL
levels correlate with sustained virologic response (SVR) rates
after interferon-based treatment of chronic hepatitis C.
METHODS: Baseline oxLDL was determined in 379 partici-
pants with chronic HCV genotype 1 infection from the INDIV-2
study using a commercial enzyme-linked immunosorbent
assay. The mechanistic in vitro studies used full-length and
subgenomic HCV genomes replicating in hepatoma cells.
RESULTS: In the multivariate analysis, oxLDL was found to be
an independent predictor of SVR. Oxidized LDL did not corre-
late with markers of inﬂammation (alanine transaminase,
ferritin), nor was serum oxLDL affected by exogenous inter-
feron administration. Also, oxLDL did not alter the sensitivity of
HCV replication to interferon. However, oxLDL was found to be
a potent inhibitor of cell-to-cell spread of HCV between adja-
cent cells in vitro. It could thus reduce the rate at which new
cells are infected by HCV through either the cell-free or cell-to-
cell route. Finally, serum oxLDL was signiﬁcantly associated
with the estimated infected cell loss rate under treatment.
CONCLUSIONS: Oxidized LDL is a novel predictor of SVR after
interferon-based therapy and may explain the previously
observed association of LDL with SVR. Rather than being a
marker of activated antiviral defenses it may improve chances of
SVR by limiting spread of infection to naive cells through the cell-
to-cell route. (Cell Mol Gastroenterol Hepatol 2015;1:285–294;
http://dx.doi.org/10.1016/j.jcmgh.2015.03.002)
Keywords: Cell-to-Cell Spread; oxLDL; SVR; SR-BI.he hepatitis C virus (HCV) is a small enveloped virusTwith a single-stranded, positive-sense RNA genome.
It has chronically infected an estimated 160 million in-
dividuals worldwide and is a leading cause of end-stage
liver disease. Pegylated interferon a (peg-IFN) in combina-
tion with ribavirin (RBV) had long been the standard
treatment. Beginning in 2011 several direct-acting antiviral
drugs (DAA) have been approved, and more are expected to
follow.1 Currently, both peg-IFN-containing and interferon-
free treatments are available.
About half of individuals infected with HCV genotype 1
achieve sustained virologic response (SVR)—clearance of
infection—after treatment with peg-IFN/RBV.2 Numerous
factors have been associated with interferon responsiveness
and eventual SVR. These have been reviewed elsewhere.3
Notably, genetic and nongenetic factors interact to deter-
mine chances of SVR.4 Among the biochemical parameters,
high low-density lipoprotein (LDL)5–8 and low g-glutamyl-
transpeptidase9 seem to be strongly predictive of SVR.
However, for these and most other factors the mechanism of
how they are linked to interferon responsiveness is unclear,
so our ability to predict treatment outcome in individual
patients remains unsatisfactory.
There are multiple interconnections between the HCV
replication cycle and host lipid metabolism: HCV particle
assembly is linked to the host cell’s very-low-density lipo-
protein synthesis machinery, resulting in the release of
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components.10–13 Indeed, HCV particles produced in cell
culture (HCVcc) appear to be less dense and larger than
expected for a member of the Flaviviridae. Moreover, HCVcc
are heterogeneous in size, and larger particles appear to be
more highly infectious.14,15 An essential HCV receptor on
hepatocytes is scavenger receptor class B type I (SR-BI),16
physiologically the main receptor for high-density lipopro-
tein on hepatocytes. The LDL receptor, on the other hand,
has long been proposed to also be involved in HCV cell
entry,17 but its exact role has remained controversial, and
unlike SR-BI it has not been shown to be essential for pro-
ductive infection.18
Despite these clear links between the HCV replication
cycle and both very-low-density lipoprotein and high-
density lipoprotein, LDL is the lipid species most consis-
tently associated with SVR after peg-IFN/RBV as well as
ﬁrst-generation telaprevir-based triple therapy.5–8,19 This is
somewhat puzzling because the link between LDL and HCV
biology is not obvious. We have previously identiﬁed and
characterized oxidized low-density lipoprotein (oxLDL)—a
naturally occurring derivative of native LDL that has un-
dergone oxidative modiﬁcations—as a potent endogenous
inhibitor of HCV cell entry.20,21 In vivo oxLDL is detectable
at low levels in human serum. Oxidized LDL binds to SR-BI,
and our earlier work suggested that it perturbs the inter-
action between HCV and SR-BI in a noncompetitive manner.
Moreover, we were able to show that endogenous oxLDL,
like the in vitro generated oxLDL which is mostly used for
experimentation, inhibits HCV infectivity. However, whether
endogenous oxLDL has an impact on interferon respon-
siveness in the setting of chronic HVC infection is unknown.
This study was undertaken to address this question.
Materials and Methods
Patient Cohort
We examined the samples and clinical data of 379
treatment-naive patients infected with HCV genotype 1 from
the treatment arm of the INDIV-2 study. Details of the study
have been described elsewhere.22 Brieﬂy, the patients
received peg-IFN/RBV for 24–72 weeks depending on their
baseline viral load and on-treatment viral kinetics. The
INDIV-2 study protocol was approved by the independent
ethics committees at all 20 German study centers.Oxidized Low-Density Lipoprotein
Enzyme-Linked Immunosorbent Assay
To quantify serum oxLDL, we used a commercial
enzyme-linked immunosorbent assay system (cat. no. 10-
1143-01; Mercodia, Uppsala, Sweden) that we had previ-
ously evaluated.21Cell Lines and Reagents
Huh-7 and Huh-7.5 cells were maintained in Dulbecco’s
modiﬁed Eagle medium (DMEM) (cat. no. 11966-025; Life
Technologies, Darmstadt, Germany) supplemented with
10% fetal calf serum (cat. no. F7524-500ML; Sigma-Aldrich,Munich, Germany), nonessential amino acids (cat. no.
11140-035; Life Technologies), L-glutamine (cat. no. 25030-
024; Life Technologies), and penicillin/streptomycin
(cat. no. A 2212; Biochrom, Berlin, Germany). Oxidized LDL
was purchased from Intracel Resources (cat. no. RP-047;
Frederick, MD) and LDL from Kalen Biomedical (cat. no.
770200-4; Montgomery Village, MD). Peg-IFN for in vitro
experimentation was obtained from Roche Pharma (Basel,
Switzerland).
Plasmids
For pseudo-particle production, we used the following
three plasmids: (1) a vector expressing the human immu-
nodeﬁciency virus (HIV) gag and pol genes (HIV gag-pol), a
plasmid encoding the G-protein of the vesicular stomatitis
virus, and pTRIP-tagRFP-NLS-IPS1 encoding red ﬂuorescent
protein (RFP) fused to a nuclear localization signal (NLS)
and the mitochondrial anchor domain of IPS1 (interferon
promoter stimulator-1).23 The plasmids pFK_JFH1/J6/
C-846.dg and pFK_i389luc_EL_JFH1/J6/C-846.dg encoding
the full-length chimeric HCV genotype 2a genome Jc1 with
or without a ﬁreﬂy luciferase reporter (Jc1 and Fluc-Jc1,
respectively) have been described by Pietschmann et al.24
Moreover, subgenomic replicons containing a luciferase
reporter representing genoytpes 2a (Luc-JFH1-NS3-5B) and
1b (Fluc-Con1 NS3-5B) were used.
Production of Pseudo-particles and Transduction
of Target Cells
Pseudo-particles encoding the tagRFP-NLS-IPS1 reporter
were produced as previously described elsewhere.25 Brieﬂy,
human embryonic kidney 293T (HEK293T) cells (8  105
cells/well) were seeded onto a six-well plate 1 day before
transfection. Three plasmids expressing HIV gag-pol, tagRFP-
NLS-IPS1 and the G-protein of the vesicular stomatitis virus
were mixed with OptiMEM (cat. no. 31985-047; Gibco/Life
Technologies, Darmstadt, Germany) and polyethylenimine
(cat. no. P4707-50ML; Sigma-Aldrich) as a transfection re-
agent. The mixture was incubated for 20 minutes at room
temperature. Seeded cells were washed once with 1x
phosphate-buffered saline (PBS), and 1 mL of fresh DMEM
supplemented with 3% fetal calf serum, L-glutamine and
nonessential amino acids was added. After incubation, 80 mL
of the transfectionmixture was added per well and incubated
at 37C. The mediumwas changed 6 hours after transfection.
The pseudo-particle–containing supernatant was harvested
48 and 72 hours after transfection and pooled. The ﬁltered
supernatant was used to transduce Huh-7.5 cells. To this end,
cells were incubated for 8 hours with pseudo-parti-
cle–containing supernatant before the medium was changed.
The transduction efﬁciency was determined by ﬂow cytom-
etry (Supplementary Figure 1).
Flow Cytometry
Cell populations expressing an RFP reporter were tryp-
sinized and resuspended with DMEM complete. The cells
were washed two times with 1x PBS before being resus-
pended in 1x PBS to a ﬁnal cell number of 2  106 cells/mL.
May 2015 oxLDL Predicts Interferon Responsiveness 287Cells were analyzed using a FACS Canto2 cytometer (BD
Biosciences, Heidelberg, Germany).
Hepatitis C Virus RNA Transcription
We produced HCV RNA by in vitro transcription, as
described by Koutsoudakis et al.26 Brieﬂy, plasmid DNA
encoding full-length HCV genomes or subgenomic HCV
replicons was linearized by digestion with Mlu1 (cat. no.
R0198L; NEB, Frankfurt am Main, Germany) for 1 hour at
37C. Linearized DNA was puriﬁed by phenol/chloroform
extraction (cat. no. 0038.1, Roti-Phenol: Carl Roth, Karls-
ruhe, Germany; chloroform, cat. no. 3313.1: Carl Roth),
precipitated with ethanol, and dissolved in high-perfor-
mance liquid chromatography (HPCL) water (cat. no.
A511.2; Carl Roth). The in vitro transcription reaction
mixture contained 80 mM HEPES [4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, pH 7.5] (cat. no. HN77.1;
Carl Roth) 12 mM MgCl2 (cat. no. HNO3.1; Carl Roth), 2 mM
spermidine (cat. no. SO266-5G; Sigma-Aldrich), 40 mM
dithiothreitol (DTT) (cat. no. 43915-5G; Sigma-Aldrich), a
3.125 mM concentration of each nucleoside triphosphate
(cat. no. 11140957001, 11140922001, 11140965001,
11140949001; Roche, Basel, Switzerland), 1 U of RNasin/
mL (cat. no. N2515; Promega, Mannheim, Germany), 0.1 mg
of plasmid DNA/mL, and 0.6 U of T7 RNA polymerase/mL
(cat. no. P2077; Promega). After 2 hours of incubation at
37C, 0.3 U T7 RNA polymerase was added to the mixture
and incubated for another 2 hours at 37C. The reaction was
terminated by adding 1.2 U of DNase (cat. no. M6101;
Promega) for 30 minutes at 37C. After in vitro transcrip-
tion, the RNA was puriﬁed by phenol/chloroform extraction
(Roti-Aqua-Phenol, cat. no. A980.2; Carl Roth), precipitated
with isopropanol, and dissolved in HPCL water. The RNA
content and purity was determined using NanoDrop
(Thermo Scientiﬁc, Schwerte, Germany).
Hepatitis C Virus Replication Assay and
Luciferase Assay
For the replication assay, the cells were trypsinized and
resuspended with DMEM complete. The cells were then
washed with 1x PBS and resuspended to a ﬁnal cell number
of 1.5  107/mL cells in Cytomix (120 mM KCl, 0.15 mM
CaCl2, 10 mM K2HPO4/KH2PO4, 25 mM HEPES [4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid], 2 mM
EGTA, 5 mM MgCl2, [pH 7.6]) supplemented with 2 mM ATP
(cat. no. A2383-25G; Sigma-Aldrich) and 5 mM glutathione
(cat. no. G4251-5G; Sigma-Aldrich). The cells were trans-
fected with 5 mg in vitro transcribed HCV RNA by electro-
poration using the Gene Pulser system (BioRad
Laboratories, Munich, Germany). We transferred 400 mL of
cell suspension into a cuvette with a gap width of 0.4 cm
(BioRad Laboratories), and the pulse was set under the
following conditions: 270 V and 960 mF. Transfected cells
were transferred to 37.5 mL of fresh DMEM complete and
were seeded onto a 96-well plate (2  104 cells/well)
(Sarstedt, Nümbrecht, Germany).
At 4 hours after transfection, the medium was changed
to medium containing different concentrations of peg-IFN(0, 0.1, 0.3, 1, 3, 10, 30, 100 ng/mL) with or without a
single IC50 dose of oxidized LDL. The medium was changed
every 24 hours to refresh the interferon and oxLDL.
Transfection was stopped 24, 48, and 72 hours after
transfection, and the luciferase activity was measured.
Brieﬂy, the transfected cells were washed one time with 1x
PBS and lyzed directly on the plate with 35 mL of ice-cold
lysis buffer (0.1% Triton X-100, 25 mM glycylglycine, 15
mM MgSO4, 4 mM EGTA, and 1 mM DTT; pH 7.8) and
frozen. We then transferred 20 mL of the thawed and
resuspended cells to a white 96-well plate (Lumitrac 600;
Sigma-Aldrich). We measured the luciferase activity using a
Luminometer Model 9100-002 (Turner BioSystems, Sun-
nyvale, CA) after the addition of 72 mL of assay buffer (25
mM glycylglycine, 15 mM MgSO4, 4 mM EGTA, 1 mM DTT, 2
mM ATP, 15 mM K2PO4, pH 7.8) and 42 mL of luciferin so-
lution (200 mM luciferin, 25 mM glycylglycine, pH 8.0). The
50% inhibitory concentration of peg-IFN in the presence or
absence of oxLDL was determined using GraphPad Prism 5
(GraphPad Software, La Jolla, CA).
Cell-to-Cell-Spread Assay
To assay the HCVcc spread through the cell-to-cell route,
we performed a modiﬁed version of the agarose overlay
assay previously described elsewhere.27 Brieﬂy, target Huh-
7.5 cells were transduced with a tagRFP-NLS-IPS1 reporter
construct.23 The encoded red ﬂuorescent protein (tagRFP)
fusion protein is tethered to the mitochondrial membrane in
uninfected cells resulting in a perinuclear staining pattern.
Upon HCV infection, the reporter fusion protein is cleaved
from its mitochondrial anchor by the HCV NS3/4A protease,
and due to a nuclear localization sequence it relocates to the
nucleus, resulting in nuclear staining.
Huh-7.5 cells were transfected with Jc1 HCV RNA (donor
cells) and incubated for 24 hours. Donor cells were mixed
with naive target cells at a 1:1 ratio and seeded into 24-well
plates. As soon as cells had settled (after 4 hours), the cell
mixture was overlaid with medium (DMEM complete) con-
taining 2% SeaPlaque low-melting-temperature agarose
(cat. no. 50101; Lonza, Cologne, Germany) to block the virus
spread through the cell-free route. The overlay was sup-
plemented with a IC90 dose of oxLDL or native LDL as
control. Cells were incubated for 96 hours at 37C. The cell-
to-cell spread of HCV to target cells was monitored by
ﬂuorescent microscopy (DMI6000; Leica, Wetzlar, Ger-
many). After 96 hours of coculture, the percentage of HCV-
positive target cells was determined.Software and Statistical Analyses
Statistical analyses of clinical data were performed with
the SPSS software package (IBM, Armonk, NY). The Mann-
Whitney U-test, Spearman correlation, receiver operating
characteristic (ROC) analysis to determine the area under
the ROC curve values and cutoff points, DeLong test, Fisher’s
exact test, and chi-square test were performed as appro-
priate. A standard viral kinetic model was used to estimate
the viral kinetic parameters and ﬁt viral kinetics. Based on a
maximum likelihood approach, we estimated the infected
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values for other viral and pharmacokinetic parameters.28
All in vitro experiments were repeated on three or more
separate occasions. Numerical data from in vitro experi-
mentation were analyzed using an unpaired two sided t-test
in Excel (Microsoft, Redmond, WA), and GraphPad Prism
5 was used to ﬁt the sigmoidal concentration-response
curves.
Results
Oxidized Low-Density Lipoprotein Is an
Independent Predictor of Sustained
Virologic Response
Serum oxLDL levels at baseline (ie, before treatment
was started) were determined in 379 chronically HCV ge-
notype 1 infected individuals from the INDIV-2 study.22 All
had subsequently received treatment with peg-IFN/RBV.
The serum oxLDL was statistically signiﬁcantly higher in
those who achieved SVR compared with those who did not
(7.1 mU/L vs 5.9 mU/L; P < 0.001) (Figure 1A). Conversely,
when patients were grouped into three-thirds with low,
medium, and high serum oxLDL at baseline, the SVR rates
were higher in groups with higher serum oxLDL (44%,
54%, and 65% in the low, intermediate, and high oxLDL
groups) although only the comparison between the low and
high oxLDL group reached statistical signiﬁcance
(Figure 1B).
In a univariate analysis, both LDL and oxLDL as well as
other known predictors of treatment response were signif-
icantly associated with SVR (Table 1). Upon multivariate
analysis, oxLDL but not native LDL remained as an inde-
pendent predictor of SVR. In a ROC curve analysis, the area
under the ROC curve values for oxLDL and LDL were not
statistically signiﬁcantly different (DeLong test, P ¼ 0.82)
with 0.608 (95% conﬁdence interval [CI], 0.55–0.67) and
0.615 (95% CI, 0.56–0.67), respectively. This indicates that
as a clinical test both parameters are largely equivalent.Figure 1. Baseline serum oxidized low-density lipoprotein
(SVR). Serum oxLDL levels of 379 patient sera from the INDIV-2
immunosorbent assay. (A) Serum oxLDL in individuals (n¼ 206) w
Non-SVR). (B) SVR rate in patient subgroups with low, intermed
Student unpaired t test.Optimal cutoff points in our cohort were determined to be
8.85 mU/L for oxLDL and 3.6 mmol/L for LDL.
Oxidized Low-Density Lipoprotein Correlates
With Native Low-Density Lipoprotein but Not
With Markers of Inﬂammation
There are several conceivable explanations for the as-
sociation of oxLDL with SVR. One hypothesis was that
elevated oxLDL may be associated with inﬂammation and as
such might indicate an already ongoing antiviral response.
However, there was no correlation between serum oxLDL
and alanine transaminase as a marker of hepatic inﬂam-
mation (Figure 2A) or ferritin as a marker of systemic
inﬂammation (see Figure 2B). There was, however, a clear
and signiﬁcant correlation between serum oxLDL and native
LDL (see Figure 2C).
Oxidized Low-Density Lipoprotein Serum Levels
Are Not Affected by Interferon
Alternatively, generation of oxLDL might be enhanced
under conditions of interferon stimulation, thus it would be
an indicator of activated innate antiviral defenses. We
examined oxLDL serum levels during the ﬁrst 2 weeks
of peg-IFN/RBV administration in 26 patients from the
INDIV-2 cohort. Overall, serum oxLDL remained unchanged
(see Figure 2D). When subgroups with SVR, null response,
or relapse were examined, there was also no discernible
change (data not shown). Thus, serum oxLDL level appears
independent of interferon stimulation.
Oxidized Low-Density Lipoprotein Does Not Alter
Interferon-Sensitivity of Hepatitis C Virus
A second hypothesis was that oxLDL enhances the anti-
viral effect of exogenous interferon on HCV replication. To
test this, we determined the concentration response curves
for HCV inhibition by peg-IFN in the presence and absence(oxLDL) is associated with sustained virologic response
cohort were determined by commercial oxLDL enzyme-linked
ho achieved SVR compared with those who did not (n ¼ 173;
iate, and high baseline oxLDL. P values were determined by
Table 1.Predictors of Sustained Virologic Response (SVR): Factors at Baseline That Were Associated With SVR Identiﬁed by Univariate and Multivariate Analysis
Clinical Parameter at
Baseline
SVR P value
Positive (n ¼ 206)a Negative (n ¼ 173)a Univariate Analysis Multivariate Analysis
Age (y) 41.8 ± 10.7 (18–68) 44.9 ± 11.0 (19–68) <.001 .1
oxLDL (mU/L) 7.1 ± 3.2 (1.2–21.9) 5.9 ± 2.6 (1.2–13.3) <.001 <.001
Total cholesterol (mmol/L) 5.1 ± 1.2 (2.8–9.0) 4.7 ± 1.1 (1.5–8.3) <.002 .2
HDL (mmol/L) 1.1 ± 0.4 (0.4–2.5) 1.1 ± 0.4 (0.4–3.0) .09 .7
LDL (mmol/L) 3.5 ± 1.0 (1.5–6.3) 3.1 ± 0.9 (0.4–6.1) <.001 .2
Triglycerides (mmol/L) 1.1 ± 0.5 (0.4–3.9) 1.1 ± 0.5 (0.2–3.6) .8 .2
GGT (U/L) 49.2 ± 50.6 (6.0–431.0) 88.5 ± 82.3 (10.0–627.0) <.001 .03
ALT (U/L) 80.2 ± 53.3 (11.0–357.0) 82.1 ± 59.0 (18.0–450.0) .8 .004
ALP (U/L) 66.3 ± 18.6 (33.0–181.0) 74.0 ± 23.7 (32.0–204.0) <.002 .007
Bilirubin (mg/dL) 1.5 ± 3.5 (0.2–37.0) 1.7 ± 3.2 (0.2–22.0) .3 .3
Ferritin (mg/L) 133.4 ± 122.6 (3.7–780.0) 217.1 ± 237.9 (6.0–18,46.0) <.001 <.001
Platelets (Tsd/mL) 242.6 ± 57.4 (123.0–445.0) 236.6 ± 66.9 (69.0–433.0) .7 .9
HCV RNA (IU/mL) 975,207 ± 1,340,103 (615–7,575,860) 1,116,731 ± 1,384,396 (615–7,692,310) <.003 .02
IL28B rs12979860, C allele
present/absent (no data)
170/24 (12)b 126/34 (13)b <.002 .003
ALT, alanine transaminase; ALP, alkaline phosphatase; GGT, g-glutamyltranspeptidase.
aMean ± standard deviation with range in parentheses.
bDenotes number of individuals.
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senting genotypes 1b (Con1 isolate; Figure 3A) and 2a
(JFH1; see Figure 3B) and for a full-length genotype 2a
genome (Jc1; see Figure 3C), the IC50 was similar in the
presence or absence of oxLDL. Similar results were
observed when a full-length genotype 2a genome replication
was analyzed in Huh-7 cells that have more intact innate
antiviral defenses compared with Huh-7.5 (see Figure 3D).
Thus, oxLDL does not alter interferon-sensitivity of HCV
replication in this experimental system.Oxidized Low-Density Lipoprotein Is a Potent
Inhibitor of the Cell-to-Cell Spread of Hepatitis
C Virus
A third hypothesis was that oxLDL may improve treat-
ment outcome by reducing infection of new hepatocytes
during peg-IFN/RBV treatment, resulting in a faster decline
in the pool of infected cells. Spread to uninfected cells in the
setting of established chronic infection is thought to occur to
a large extent through the cell-to-cell route. The effect of
oxLDL on cell-to-cell spread is unknown. In an experiment
where HCV-infected donor cells were mixed with uninfected
acceptor cells, and spread through the cell-free route was
prevented with an agarose overlay, we found that oxLDL
potently inhibited cell-to-cell spread between adjacent cells
with 37.8%, 41.8%, and 12.6% of acceptor cells becoming
infected in the untreated, native LDL, and oxLDL treated
groups, respectively (Figure 4A–E).Serum Oxidized Low-Density Lipoprotein Is
Associated With Second Slope Decline in
Viral Load
In interferon-based treatment of chronic HCV infection,
decline of viral load during the second phase is thought to
be driven by the rate of infected cell loss (d), which is an
important predictor for treatment response. Thus, we
analyzed whether oxLDL is correlated with d. We used viral
kinetics data available from the INDIV-2 study to correlate
this estimated viral kinetic parameter with serum oxLDL
and found a modest yet signiﬁcant correlation (Figure 5).Discussion
In this work, we show that baseline oxLDL is an inde-
pendent predictor of response to peg-IFN/RBV treatment of
chronic HCV genotype 1 infection. We provide data showing
that oxLDL is not a marker of inﬂammation or a modulator
of interferon responsiveness per se, but is a potent inhibitor
of HCV cell-to-cell spread. Thus, conceivably oxLDL might
enhance the likelihood of treatment response by limiting the
rate at which new cells are infected during treatment.
From a clinical point of view, we have identiﬁed a novel
predictor of SVR after interferon-based treatment of chronic
hepatitis C. Although interferon-free regimens now offer
higher SVR rates and fewer side effects compared with
interferon-containing regimens, they are also much more
costly.1 Thus, peg-IFN may continue to be used for some
time, especially in settings where cost is an issue. An abilityFigure 2. Oxidized low-
density lipoprotein
(oxLDL) correlates with
native LDL but not with
markers of inﬂammation
and is unaffected by
interferon administration.
Baseline serum oxLDL
plotted against baseline (A)
alanine transaminase, (B)
ferritin, and (C) native LDL.
R describes the Spearman
rank correlation. (D) In 26
patients serum oxLDL level
were determined at base-
line (BL) as well as week 1
(TW1) and 2 (TW2) of
pegylated interferon a/
ribavirin (peg-IFN/RBV).
Data are shown as mean ±
standard deviation for the
respective groups.
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based regimen and who is likely to require a more costly
interferon-free regimen is thus clinically useful. However,
because serum LDL is widely available as a clinical test and
correlates strongly with oxLDL, it is both reasonable and
cost-effective to determine LDL instead of oxLDL as a pre-
dictor for therapy outcome in the clinical setting, given that
the AUC for both tests is very similar. Whether oxLDL also
predicts SVR in the setting of DAA-containing regimens re-
mains to be established. However, it has been reported that
baseline LDL is associated with SVR in patients receiving
triple therapy with peg-IFN/RBV plus the ﬁrst generation
NS3/4A protease inhibitor telaprevir.19 This may suggest
that in this regimen oxLDL would also be predictive, given
that in our cohort oxLDL correlates with native LDL but only
oxLDL remains as an independent predictor after multi-
variate analysis. Indeed, several previous studies had
observed a correlation of baseline LDL with SVR,5–8 but
there was no obvious explanation for this because LDL is
not known to directly affect the HCV replication cycle. Our
data suggest that these observations may have been sec-
ondary to the correlation of LDL with oxLDL.
We tested three different hypotheses as to why oxLDL
might predict SVR. First, it has been suggested that oxLDL
may be associated with the grade of inﬂammation in in-
dividuals with HCV infection.29 It has also been linked toFigure 3. Oxidized LDL (oxLDL) does not alter interferon s
in vitro. Huh-7.5 cells were transfected either with HCV RNA en
(B) a genotype 2a NS3-5B subgenome (isolate JFH1), (C) a geno
luciferase reporter in a separate cistron. (D) Huh-7 were transfe
cases, the cells were treated with increasing concentrations of p
10 mg/mL oxLDL. Luciferase activity was determined as a mea
mean ± standard deviation from a representative of three indepsystemic inﬂammation.30 Although to our knowledge no
direct link to antiviral responses has been established,
oxLDL could be a marker of inﬂammation or even an
ongoing antiviral response and thus could predict the
chances of achieving SVR through administration of exoge-
nous interferon. However, oxLDL neither correlates with
alanine transaminase as a marker of hepatic inﬂammation
nor with ferritin, a well-known acute phase reactant. Of
note, ferritin is also elevated in iron overload and advanced
hepatic ﬁbrosis among patients with nonalcoholic fatty liver
disease.31,32 Serum oxLDL itself was not affected by
administration of exogenous interferon, suggesting that its
serum levels are largely independent of the activation of the
innate antiviral defences. Second, oxLDL might increase the
sensitivity of replicating HCV to interferon. However, using
state-of-the-art in vitro models of HCV infection, that is,
subgenomic and full-length genomes of HCV genotypes 1
and 2 replicating in Huh-7 or Huh-7.5 cells, the concen-
tration–response curve of peg-IFN inhibition of HCV repli-
cation was not altered in the presence of oxLDL, arguing
against this explanation.
A third hypothesis is that endogenous oxLDL has a
beneﬁcial effect in the setting of peg-IFN/RBV treatment
because as an HCV entry inhibitor it inhibits the infection of
previously uninfected cells which in part drives infected cell
loss during the untreated steady state. The pool of infectedensitivity of replicating hepatitis C virus (HCV) genomes
coding (A) a genotype 1b NS3-5B subgenome (isolate Con1),
type 2a full-length genome (Jc1 chimera) all containing a ﬁreﬂy
cted with full-length Jc1 with a ﬁreﬂy luciferase reporter. In all
egylated interferon a (peg-IFN) in the presence or absence of
sure of RNA replication. Individual data points represent the
endent experiments performed in triplicate.
Figure 4. Oxidized LDL (oxLDL) is an inhibitor of hepatitis C virus (HCV) cell-to-cell spread. Inhibition of cell-to-cell spread
by oxLDL was analyzed by coculturing unmarked HCV-infected Huh-7.5 donor cells with HCV-naive Huh-7.5 target cells
expressing a tagRFP-NLS-IPS1 reporter (red ﬂuorescence) (see Materials and Methods for details). Nuclei were stained with
40,6-diamidino-2-phenylindole. Nuclear red ﬂuorescence indicates infected target cells, and a mitochondrial staining pattern
indicates uninfected target cells. Representative images are shown from an experiment where (A) mock electroporated donor
cells were used and from experiments where donor cells had been electroporated with full-length HCV genomes and where
seeded in the (B) absence or (C) presence of LDL (10 mg/mL) or (D) in the presence of oxLDL (10 mg/mL). (E) Results from the
experimental conditions shown in B–D were quantiﬁed by counting noninfected and infected target cells and determining the
percentage infected after 96 hours of coculture. Data represent the mean ± standard deviation from a representative
experiment performed in triplicate counting ﬁve visual ﬁelds per well with 40–188 (mean 94 ± 43) reporter cells per visual ﬁeld.
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disappear through cure or removal and the rate at which
naive cells get infected.33,34 The slower second phase
decline of viral load during interferon-based therapy is
thought to reﬂect a declining pool of infected hepatocytes;Figure 5. Modest yet signiﬁcant correlation of baseline
serum oxidized low-density lipoprotein (oxLDL) with the
estimated infected cell loss rate d. Correlation of baseline
serum oxLDL with the estimated infected cell loss rate d. R
describes the Spearman rank correlation.and the slope of second-phase decline and even more the
estimated viral kinetic parameter describing the infected
cell loss rate are predictive of eventual SVR. Presence of an
agent reducing the rate at which naive cells get infected
might thus be beneﬁcial. We found that oxLDL but not LDL
potently inhibits cell-to-cell spread between neighboring
cells. Cell-to-cell spread is thought to be the dominant route
of new cell infection within the chronically infected
liver.35,36 Certainly, this does not prove the hypothesis that
serum oxLDL promotes viral clearance through acceleration
of the decline of the pool of infected cells, but it is at least
consistent with it. We also observed a modest yet signiﬁcant
correlation between baseline serum oxLDL and the esti-
mated infected cell loss rate. Again, this is not proof but a
ﬁnding that is consistent with a reduced rate of new cell
infection. Finally, our observations that oxLDL inhibits cell-
to-cell spread together with previously published data
suggesting that oxLDL inhibits HCV cell entry by perturbing
the interaction between the virus and SR-BI21 seem to
suggest that HCV uses SR-BI for cell-to-cell spread as well as
for infection through the cell-free route.37,38
Whether inhibition of viral entry is a useful thera-
peutic approach in the setting of established chronic
infection is unclear: a recent phase I trial of ITX-5061
(N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-
2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoace-
tamide;hydrochloride), the most advanced inhibitor of
HCV entry in clinical development, reported no signiﬁcant
effect of the drug on viral load in monotherapy.39 How-
ever, the effect of ITX-5061 on HCV entry is modest even
May 2015 oxLDL Predicts Interferon Responsiveness 293in vitro.40 Erlotinib, a drug already approved for anti-
tumor therapy that inhibits epidermal growth factor re-
ceptor signaling and thereby HCV cell entry,41 is only just
beginning clinical evaluation for HCV infection. However,
if cell entry inhibition had indeed a positive impact on the
efﬁcacy of interferon treatment in chronic viral hepatitis
C, this might have implication for other forms of chronic
viral hepatitis as well. Our data suggest that a combina-
tion of interferon with inhibitors of viral entry holds
promise even in the setting of established chronic hepa-
titis. However, data from treatment studies will be needed
to clarify the true potential of such an approach.
In summary, our work has several implications. (1) Even
as all oral regimens begin to reach the market, interferon-
based treatment will continue to be used in settings with
cost restraints. Thus, there is a need for predictors of who is
likely to respond to interferon and who will require a more
expensive DAA combination regimen. (2) We show that
oxLDL very likely explains why several previous studies
found an association between native LDL and SVR. (3) Our
data support that SR-BI is required for HCV cell-to-cell
spread and that this route can be blocked by oxLDL. (4)
Most importantly, we provide data suggesting that oxLDL is
neither a marker of inﬂammation nor a modulator of the
interferon response but might enhance SVR rates by limiting
the rate of viral spread to uninfected cells. This ﬁnding may
even be relevant for other forms of chronic viral disease as
it suggests that entry inhibition may have a beneﬁcial effect
even in the context of already established infections.References
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Supplementary Figure 1. Expression level of red ﬂuores-
cence protein (RFP) in transduced Huh-7.5 cells. Huh-7.5
cells were transduced with tagRFP-NLS-IPS1, and expres-
sion level of RFP was determined by ﬂuorescence-activated
cell sorting analysis compared with naive Huh-7.5 cells
immediately before cell-to-cell spread experiments were
performed.
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